[1] Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287(19): 2570-2581. doi:10.1001/jama.287.19.2570
[2] Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234. doi:10.1056/NEJM199807233390404
[3] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–853.
[4] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 (15):1577–1589. doi:10.1056/NEJMoa0806470
[5] Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15-18. doi:10.1136/bmj.322.7277.15
[6] Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A,Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications trial. Diabetes Care 2002; 25(2):275–278. doi:10.2337/diacare.25.2.275
[7] Leiter A, Lundman P, da Sliva PM. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidemia International Study. Diabet Med 2011; 28 (11):1343-1351. doi:10.1111/j.1464-5491.2011.03360.x
[8] Yang W, Lu J, Weng J. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362 (12):1090-1010. doi:10.1056/NEJMoa0908292
[9] Bjornstad P, Eckel RH. Pathogenesis of Lipid Disorders in Insulin Resistance: A Brief Review. Curr Diab Rep 2018; 18(12):127.doi:10.1007/s11892-018-1101-6
[10] Lebovitz HE, Ludvik B, Yaniv I, Haddad W, Schwartz T, Aviv R. Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabetic Med. 2013; 30(6):687–693. doi:10.1111/dme.12132
[11] Ji L, Weng J, Lu J, Guo X, Yang W, Jia W, et al. Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China. J Endocrinol Invest 2014; 37(9):843-52. doi:10.1007/s40618-014-0115-4
[12] Haseeb Ahmad Khan. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol 2007; 44(4):193-200. doi:10.1007/s00592-007-0003-x
[13] Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007; 7(1):24-29. doi:10.1007/s10238-007-0121-3
[14] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. doi:10.1001/jama.285.19.2486
[15] Sunjaya AP, Sunjaya AF. Glycated hemoglobin targets and glycemic control: Link with lipid, uric acid and kidney profile. Diabetes Metab Syndr. 2018;12(5):743-748. doi:10.1016/j.dsx.2018.04.039
[16] Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Ther Adv Endocrinol Metab. 2017;8(4):51-57. doi:10.1177/2042018817692296
[17] Artha IMJR, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. Vasc Health Risk Manag 2019; 15: 149-157. doi:10.2147/VHRM.S209830
[18] Mullugeta Y, Chawla R, Kebede T, Worku Y. Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of metformin supplementation. Indian J Clin Biochem 2012;27(4):363-369. doi:10.1007/s12291-012-0225-8
[19] K P, Kunikullaya U K, Goturu J. Glycosylated Haemoglobin (HbA1c) - A Marker of Circulating Lipids in Type 2 Diabetic Patients. J Clin Diagn Res 2014; 8(2):20-23. doi:10.7860/JCDR/2014/7742.3996
[20] Dickson-Humphries T,Bottenberg B,Kuntz S.Lipoprotein abnormalities in patients with type 2 diabetes and metabolic syndrome. JAAPA 2013, 26(7): 13-18 doi:10.1097/01.jaa.0000431506.00627.be
[21] Li Z, Yang R, Xu G, Xia T. Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing. Clin Chem. 2005;51(1):144-150. doi:10.1373/clinchem.2004.038646
[22] Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8(2):206-216. doi:10.1016/j.jacl.2013.12.011
[23] Shahwan MJ, Jairoun AA, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes Metab Syndr. 2019;13(4):2387-2392. doi:10.1016/j.dsx.2019.06.009
[24] Sarfraz M, Sajid S, Ashraf MA. Prevalence and pattern of dyslipidemia in hyperglycemic patients and its associated factors among Pakistani population. Saudi J Biol Sci. 2016;23(6):761-766. doi:10.1016/j.sjbs.2016.03.001
[25] Gomez Rosso L, Lhomme M, Meroño T, et al. Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(2):188-195. doi:10.1016/j.bbalip.2016.10.014
[26] Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta. 2004;346(2):161-170. doi:10.1016/j.cccn.2004.03.030
[27] Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest. 2008;118(2):403-408. doi:10.1172/JCI33296
[28]Devroey D, Radermecker RP, Van der Schueren BJ, Torbeyns B, Jaken RJ. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS). Int J Clin Pract. 2014;68(2):180-187. doi:10.1111/ijcp.12315
[29]Alkerwi A, Pagny S, Lair ML, Delagardelle C, Beissel J. Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study. PLoS One. 2013;8(3):e57920. doi:10.1371/journal.pone.0057920
[30] Chen Y, Copeland WK, Vedanthan R, Grant E, Lee JE, Gu D, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ 2013; 347: f5446. doi:10.1136/bmj.f5446